Assessment of the Precision of the Sherlock 3CG Tip Positioning System (STAT-PICC)

This study has been terminated.
(Phase I completed. Phase II is cancelled.)
Sponsor:
Information provided by (Responsible Party):
C. R. Bard
ClinicalTrials.gov Identifier:
NCT01275430
First received: January 11, 2011
Last updated: May 25, 2016
Last verified: May 2016
  Purpose

Phase I

  • determine the location of the peripherally inserted central catheter (PICC) tip upon observation of maximum p-wave amplitude

Phase II

  • determine the precision of PICC placement in the Sherlock 3CG group versus the standard PICC placement

Condition Intervention
No Specific Conditions Under Study. Primary Focus: Adult Subjects Who Require PICC Placement
Device: Sherlock 3CG
Other: Blind Placement

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Supportive Care
Official Title: A Study to Assess the Precision of the Sherlock 3CG Tip Positioning System as a Tool to Guide Peripherally Inserted Central Catheter Placement

Further study details as provided by C. R. Bard:

Primary Outcome Measures:
  • Phase I - Location of the PICC Tip Upon Observation of Maximum P-wave Amplitude Using Sherlock 3CG. [ Time Frame: Time of PICC placement (Day 0) ] [ Designated as safety issue: No ]

    Mean distance (mm) from the PICC tip to the upper cavoatrial junction (CAJ) upon observation of maximum p-wave amplitude when using Sherlock 3CG.

    All subjects were assigned to Sherlock 3CG in Phase I. Randomization was to have occurred in Phase II, but Phase II was not initiated due to termination of the study.



Secondary Outcome Measures:
  • Phase I: Distance Necessary for Repositioning of the PICC Tip Upon Observation of the Maximum P-wave Amplitude, if Necessary. [ Time Frame: Day 0 ] [ Designated as safety issue: No ]

    Distance (mm), if any, that is required to move the PICC tip upon observation of the maximum p-wave amplitude in order to have the PICC tip at the upper cavoatrial junction. Direct measurement of distance from the catheter tips to the parts of the CAJ

    All subjects were assigned to Sherlock 3CG in Phase I. Randomization was to have occurred in Phase II, but Phase II was not initiated due to termination of the study.


  • Number of Participants With Acceptable Angiographic CT Visualization of the PICC Tip When Using Sherlock 3CG for PICC Placement [ Time Frame: Day 0 ] [ Designated as safety issue: No ]

    Proportion of acceptable visualization of the PICC tip location when maximum p-wave amplitude is observed.

    Note - this endpoint is to assess the diagnostic capability of Angiographic Computed Tomography (ACT). It is not designed to reflect on PICC tip location.

    All subjects were assigned to Sherlock 3CG in Phase I. Randomization was to have occurred in Phase II, but Phase II was not initiated due to termination of the study.


  • Phase I: Change in Distance (mm) Between the Location of the Cavoatrial Junction When Angiographic CT is Performed With the Arms Above the Head vs at the Subject's Side. [ Time Frame: Day 0 ] [ Designated as safety issue: No ]

    Measurements (mm) of the location of the cavoatrial junction on Angiographic CT to evaluate shift greater than 5mm in mediastinal structures between ACT acquisitions obtained with the arms above the head vs arms at side of body (90°).

    All subjects were assigned to Sherlock 3CG in Phase I. Randomization was to have occurred in Phase II, but Phase II was not initiated due to termination of the study.


  • Phase I: Amount of PICC Tip Movement When the Subject's Arm is Adducted From a 90° Position to the Subject's Side. [ Time Frame: Day 0 ] [ Designated as safety issue: No ]

    Mean distance (mm) of PICC tip movement when the subject's arm is adducted from a 90° position to the subject's side, by directly measuring the distance from the catheter tips to the parts of the CAJ (upper, middle, and lower) with the subject's arm at 90°and compared to the PICC tip with the subject's arm at the side .

    All subjects were assigned to Sherlock 3CG in Phase I. Randomization was to have occurred in Phase II, but Phase II was not initiated due to termination of the study.



Enrollment: 27
Study Start Date: January 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sherlock 3CG
Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
Device: Sherlock 3CG
Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
Active Comparator: "Blind" Placement
PICCs will be placed "blindly", without the use of any tip location/positioning device.
Other: Blind Placement
PICCs will be placed "blindly", without the use of any tip location/positioning device.

Detailed Description:

The feasibility phase of this study (Phase I) is a prospective, single arm, single-center feasibility study to determine the distance of the PICC tip to the upper Caval Atrial junction upon observation of maximum p-wave after PICC tip placement using the Sherlock 3CG system. Subjects judged by site personnel to require PICC placement will be screened against the study inclusion/exclusion criteria. Those subjects meeting the study criteria will be offered enrollment into the study. Informed consent will be obtained prior to subject enrollment.

PICC nurses who have been fully trained in the correct use of the Sherlock 3CG Tip Positioning System will perform the PICC placement procedures in the fluoroscopy suite. Serious adverse events (SAEs) will be collected, but collection of non-serious AEs will be limited to those adverse events (AEs) considered to be study procedure and/or device-related.

Subject follow up will be complete 30 days following the date of the study PICC procedure.

The results of the feasibility phase will be used to determine:

  1. the distance, if any, that is required to move the PICC tip upon observation of the maximum p-wave amplitude in the pivotal phase of the study (See Section 3.5.3), in order to have the PICC tip at the upper cavoatrial junction.
  2. the movement of the cardiovascular anatomy, if any, when the arm is adducted from above the head to the side of the subject.
  3. the movement of the PICC tip when the arm is moved from the 90° angle to the side.

Phase II (Pivotal) will not begin until the Phase I (feasibility) is complete. The Phase II study is a prospective, single-center, controlled, blinded, randomized study to compare the Sherlock 3CG as a tool in guiding PICC placement to the standard "blind" technique (control). Subjects judged by site personnel to require PICC placement will be screened against the study inclusion/exclusion criteria. Those subjects meeting the study criteria will be offered participation into the study. Informed consent will be obtained prior to subject enrollment. Subjects will be randomly assigned to either the Sherlock 3CG group or the control group in a 1:1 fashion. Due to the different placement techniques being utilized, the PICC nurses and study coordinator will not be blinded to the study device. PICC nurses who have been fully trained in the correct use of the Sherlock 3CG will perform the PICC placement procedures in the fluoroscopy suite. Serious adverse events (SAEs) will be collected, but collection of non-serious AEs will be limited to those AEs considered to be study procedure and/or device-related. Subject follow up will be complete 30 days following the date of the study PICC procedure.

Randomization did not occur due to early termination. All participants were assigned to Sherlock 3CG in phase I. Randomization would have occurred at the start of Phase II, but Phase II was not initiated due to early termination. Phase II was cancelled.

  Eligibility

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, age ≥ 21years
  2. Require 5 F dual lumen or 4 F single lumen PowerPICC or PowerPICC SOLO placement as part of standard care
  3. Be able to undergo study procedures
  4. Subject is able to comply with all study requirements and be available for 30 day follow-up visit.
  5. Subject has signed an Informed Consent Form (ICF) or has had an ICF signed by the subject's legally authorized representative

Exclusion Criteria:

  1. Subject has a contraindication to PICC placement as listed in the Instructions for Use (IFU) (See Section 18.2)
  2. Subject has been previously randomized for this study.
  3. Subject is unable to lie in the supine position on the fluoroscopy table
  4. Subject had radiation therapy within the last three years
  5. Subject has an existing pregnancy
  6. Subject has known glomerular filtration rate (GFR) <45 ml/min/1.73m2
  7. Subject has a functioning pacemaker or defibrillator
  8. Subject has an artificial heart or heart transplant
  9. Subject has anatomical abnormalities of the central venous system
  10. Subject has atrial fibrillation or other atrial arrhythmias in which a p-wave was not consistently present on ECG
  11. Subject has internal wires that may interfere with imaging
  12. Subject has an existing central venous catheter
  13. Subject is unable to raise arms above the head while lying down.
  14. Subject has a BMI ≥45
  15. The clinician is unable to obtain accurate external measurement due to anatomical abnormalities or personal/medical equipment.
  16. Subject has a known allergy or hypersensitivity to contrast media.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01275430

Locations
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
C. R. Bard
Investigators
Principal Investigator: Gordon McLennan, M.D. The Cleveland Clinic
  More Information

Responsible Party: C. R. Bard
ClinicalTrials.gov Identifier: NCT01275430     History of Changes
Other Study ID Numbers: BAS-3004 
Study First Received: January 11, 2011
Results First Received: July 10, 2014
Last Updated: May 25, 2016
Health Authority: United States: Institutional Review Board
Individual Participant Data  
Plan to Share IPD: No
Plan Description: Phase I was feasibility and wasn't powered. Phase II was powered, but cancelled due to slow enrollment during Phase I.

Keywords provided by C. R. Bard:
central venous catheters
peripherally inserted central catheters (PICC_
Electrocardiography (ECG)
intravascular ECG
Tip Positioning System

ClinicalTrials.gov processed this record on August 28, 2016